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Summary. Excessive fructose intake promotes the development of metabolic syndrome through the deregulation of 
metabolic pathways in the hypothalamus, liver and adipose tissue, which play crucial roles in metabolic homeostasis 
by responding to the body’s nutritional and energy requirements. Variable amounts and modes of fructose intake 
have been shown to result in different patterns of expression of metabolic disturbances, which generally include 
adiposity, insulin and leptin resistance, dyslipidemia and hypertension. We explored the possible mediatory role of 
glucocorticoid signaling on the effects of two different dietary fructose loads on hypothalamic leptin sensitivity and 
hepatic and adipose tissue lipid metabolism, which are responsible for the development of signs of metabolic syn-
drome. Experimental rats were provided with 10% and 60% fructose solutions ad libitum over a period of nine weeks. 
Our results revealed that the applied fructose had different impacts on leptin and glucocorticoid signaling and differ-
ent consequences on visceral adiposity and hepatic lipid metabolism. Only rats maintained on the high-burden 60% 
fructose diet accumulated visceral fat through the activation of adipogenic transcription factors and adipogenesis. 
This was paralleled by diminished glucocorticoid signaling in the adipose tissue and the establishment of the state of 
hypothalamic leptin resistance. The high-burden dietary fructose triggered hepatic de novo lipogenesis and a con-
comitant inhibition of β oxidation. Consumption of 10% fructose enhanced glucocorticoid signaling and lipolysis in 
the adipose tissue, creating a circulatory influx of free fatty acids and providing substrates for enhanced β oxidation 
and triglyceride synthesis in the liver. In summary, our results show that a long-term high dietary fructose load leads 
to hypothalamic leptin resistance, the development of visceral adiposity and increased hepatic de novo lipogenesis. 
Glucocorticoids regulate adipocyte storage functionality and thus may indirectly contribute to the observed changes 
in hepatic lipid metabolism, aggravating the metabolic disturbance.
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Metabolic syndrome: an escalating 
health threat to modern humanity
Metabolic syndrome is defined as a collection of inter-
connected physiological, biochemical, clinical and meta-
bolic factors that increase the risk of coronary heart disease 
(CHD), other forms of cardiovascular atherosclerotic dis-
eases (CVD) and diabetes mellitus type 2 (DMT2) (Huang 
2009). These diseases represent major mortality factors and 
escalating public-health and clinical challenges worldwide 
in the wake of urbanization, surplus energy intake, increas-
ing obesity and a more sedentary lifestyle (Kaur 2014). Al-
though there is still no consensus regarding the definition 
of metabolic syndrome, the main metabolic disturbances 
manifested are overweight/obesity, hyperglycemia, dyslip-
idemia, hypertension and insulin resistance. The origins of 
metabolic syndrome could be found in the early 1920s, when 
a Swedish physician, Kylin, demonstrated the association of 
high blood pressure with high blood glucose. In the follow-
ing decades, some authors noted that visceral obesity was 
associated with the metabolic disturbances characteristic 
for diabetes, and in 1965, Avogaro and Crepaldi described 
a syndrome comprised of hypertension, hyperglycemia and 
obesity. Significant progress in this field was achieved in 1988 
when Reaven described “a cluster of risk factors for diabe-
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tes and cardiovascular disease” and named it “Syndrome X” 
(Reaven 1988). The novelty in his contribution was the in-
troduction of the concept of insulin resistance. For a long 
time, insulin resistance has been considered the key event in 
most metabolic derangements. However, Reaven surprisingly 
excluded obesity from the definition, which was renewed in 
1989 by Kaplan, who renamed the syndrome “The Deadly 
Quartet”. In 1992, insulin resistance was acknowledged in 
the new name of the syndrome, “The Insulin Resistance Syn-
drome” (Haffner et al. 1992). The first attempt to provide a 
precise definition of metabolic syndrome was made by the 
World Health Organization (WHO) diabetes group in 1998, 
and after several modifications, two of the most adopted defi-
nitions (in effect diagnoses) were provided by the National 
Cholesterol Education Program (NCEP) Adult Treatment 
Panel III (ATP III) in 2001, and by the International Diabetes 
Foundation (IDF) criteria published in 2005 (Zimmet et al. 
2005). The NCEP ATP III included hyperglycemia/insulin 
resistance, visceral obesity, atherogenic dyslipidemia and 
hypertension as key features. This definition, which requires 
that at least three out of five criteria are met, is the most 
widely used. It also takes into consideration biochemical 
laboratory results that are easily accessible to physicians. As 
far as the IDF definition is concerned, although it relies on 
the same general criteria as other definitions, it requires obe-
sity but not necessarily insulin resistance to be present. The 
IDF criteria are widely adopted and used, but are still heav-
ily criticized for the emphasis on obesity rather than insulin 
resistance. According to this definition, about one-quarter 
of the world’s adult population has metabolic syndrome. 
Among the different risk factors for metabolic syndrome, 
such as genetic background, socioeconomic status, sedentary 
lifestyle, levels of physical activity or smoking, diet assumes a 
very important place, since the globalization of unhealthy di-
etary choices has already been positively correlated with the 
prevalence of the metabolic syndrome and its components 
(Pitsavos et al. 2006).
Dietary habits as a risk factor for 
metabolic disturbance
Increased consumption of a high-caloric modern West-
ern diet rich in sugars, trans fats, omega-6 fatty acids (FAs) 
and branched-chain amino acids is known to contribute to 
the epidemic of metabolic syndrome. One of the first cor-
relations between nutrition and health was proposed two 
decades ago when both physicians and scientists associated 
dietary fat with the rising prevalence of obesity (Golay et 
al. 1997). Consequently, a low-fat diet was introduced and 
intensively promoted; however, surprisingly this was not re-
flected in a decline in obesity. Soon after, new evidence sug-
gested that refined sugars were a very important contributing 
factor for obesity and metabolic diseases (Malik et al. 2010). 
Although sugars are naturally occurring sweeteners, humans 
have not always been the enthusiastic consumers of sugar 
we are today. Our ancestors were hunters and gatherers and 
their diet was mainly high in protein, moderate in fat and 
low in carbohydrates, the main source of which were fruits 
and berries. Intensive consumption of sugar started to in-
crease about 250 years ago, when it became widely available 
and at low cost due to colonial trade. Increased sugar con-
sumption has risen dramatically over the past few decades. It 
is also closely linked with increased consumption of a variety 
of sweetened beverages since the beginning of 20th century, 
and in the last 50 years the consumption of sugar-sweetened 
soft drinks has risen fivefold; at present, it represents more 
than 40% of the human diet. Importantly, the main source 
of sugar in beverages is high fructose corn syrup (HFCS), a 
common sweetener introduced to the food industry in the 
1960s because of its high sweetening power, organoleptic 
properties, ability to confer a long shelf-life and low produc-
tion cost (Hanover et al. 1993). The actual fructose content 
in HFCS ranges from 42-55%, and the taste and sweetness of 
55% HFCS is equivalent to that of sucrose. The next critical 
step in sugar overconsumption was related to the introduc-
tion of 55% HFCS to the carbonated-beverage industry in 
the mid-1980s. From that point on, fructose became the pre-
dominant sweetener in soft drinks (Walker et al. 2014). The 
dominance of corn syrup sweeteners (which now represent 
over 20% of total daily carbohydrate intake) was paralleled by 
a rising obesity epidemic, which prompted both clinical stud-
ies and research on animal models to understand whether 
dietary fructose intake in beverages poses a significant health 
risk. Indeed, the correlation between a high fructose diet and 
dyslipidemia was found in humans (Tappy et al. 2010), while 
animal studies indicated that dietary fructose can lead to 
obesity, insulin resistance, dyslipidemia, high blood pressure 
and type 2 diabetes (Jurgens et al. 2005). However, an impor-
tant question remained unanswered: what are the underlying 
molecular mechanisms of the metabolic effects of fructose?
The liver as a key organ involved 
in fructose metabolism 
Fructose is involved in the genesis and progression of 
metabolic syndrome through the deregulation of signaling 
and metabolic pathways in the liver and adipose tissue. The 
liver is considered the main site of the metabolism of fruc-
tose, which is readily absorbed and rapidly metabolized there 
(Tappy et al. 2010). It has been assumed that the adverse ef-
fects of fructose can be ascribed to its specific metabolic fate. 
Namely, although upon absorption in the gastrointestinal 
tract both glucose and fructose are delivered via the portal 
vein to the liver, they enter the catabolic pathways differently. 
Initial fructose cleavage in the liver bypasses the rate-limiting 
step of glycolysis, the phosphofructokinase-catalyzed conver-
sion of glucose-6-phosphate to fructose 1,6-bisphosphate, so 
that fructose can continuously enter the glycolytic pathway 
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independently of energy demands, uncontrollably producing 
glucose, glycogen, lactate and pyruvate, with further metabo-
lism providing substrates such as acyl-glycerol molecules, the 
precursors for de novo lipogenesis (Tappy et al. 2010). This 
initial difference between the hepatic metabolism of fructose 
and glucose prompted the hypothesis that the bypass of key 
feedback regulatory steps in glucose breakdown can lead to 
increased FA synthesis and the promotion of triglyceride 
overproduction after fructose utilization (Miller et al. 2008).
Another important difference between glucose and 
fructose metabolism is related to their absorption from the 
gastrointestinal tract. While glucose is transported into cells 
by the insulin-regulated glucose transporter protein GLUT-
4, fructose mainly uses high-affinity GLUT-5 transporters 
that have a low abundance in most cells (Havel 2005). Tak-
ing into account that fructose metabolism is independent 
of insulin and is directed toward increased FA synthesis, it 
is reasonable to expect that fructose overconsumption can 
ultimately lead to ectopic lipid deposition and hepatosteato-
sis. However, whether fructose overconsumption will lead to 
hypertriglyceridemia and hepatic steatosis depends on the 
balance between de novo lipogenesis and FA β oxidation. The 
master transcriptional regulator of hepatic FA oxidation is 
peroxisome proliferator activated receptor α (PPARα), which 
upon activation induces the expression of genes involved in 
mitochondrial and peroxisomal FA oxidation. In addition, 
PPARα is also involved in peripheral lipid mobilization and 
hepatic lipid droplet formation (Dalen et al. 2006). The tran-
scriptional activation of target genes by PPARα is crucially 
dependent on its coactivators, PPARγ-coactivator-1α (PGC 
1α) and lipin-1. These three proteins form a nuclear complex 
that stimulates the expression of genes involved in FA oxi-
dation, including carnitine palmitoyl transferase 1 (CPT1) 
and medium chain acyl CoA dehydrogenase (Djouadi et al. 
1999). On the other hand, the regulation of de novo lipogen-
esis in the liver is controlled by several transcription factors, 
among which are the sterol response element binding pro-
teins (SREBPs). SREBP-1c specifically regulates hepatic tri-
glyceride synthesis through the expression of several down-
stream target genes, such as acetyl CoA carboxylase (ACC) 
and fatty acid synthase (FAS) (Horton et al. 2002). It was 
previously demonstrated that a high-fructose diet leads to 
increased expression of FAS in the liver and concomitantly to 
ectopic lipid accumulation and hypertriglyceridemia. How-
ever, the mechanism of this hyperlipidemic effect of fructose 
remains controversial, since it was reported that only a small 
percentage of ingested fructose appears to be directly con-
verted to plasma triglycerides (Sun et al. 2012).
Visceral adipose tissue and 
regulation of energy balance
Apart from the liver as the main site of carbohydrate 
metabolism, dietary fructose can also contribute to the devel-
opment of metabolic syndrome through the deregulation of 
metabolic pathways in the hypothalamus-adipose tissue axis, 
which has a crucial role in the body’s response to nutritional 
and energy requirements. The most prominent early hall-
mark of diet-induced dysfunction of the hypothalamus-adi-
pose tissue axis is the development of leptin resistance, a state 
associated with visceral fat accumulation (Oswal et al. 2010). 
The hypothalamus is the brain region critically involved in 
the regulation of food intake, body weight and energy ex-
penditure. Leptin is an anorexigenic hormone produced by 
the adipose tissue in proportion to its mass. Leptin regulates 
food intake and hence body adiposity through modulation of 
the synthesis and secretion of both orexigenic and anorexi-
genic peptides in the hypothalamic nuclei (Friedman et al. 
1998). Leptin signaling is conducted through the long form 
of the leptin receptor (Ob-Rb), which upon leptin binding, 
stimulates tyrosine Janus kinase 2 (JAK2) and activates the 
signal transducer and activator of transcription 3 (STAT3) 
protein by phosphorylation, dimerization and translocation 
to the nucleus. However, the leptin signaling pathway is con-
strained by different feedback inhibitors, such as suppressor 
of cytokine signaling 3 (SOCS3) whose induction in the hy-
pothalamus is one of several mechanisms that contribute to 
leptin resistance. Leptin resistance is also related to impaired 
leptin transport across the blood-brain barrier, as well as to 
defects in hypothalamic Ob-Rb signal transduction resulting 
from reduced Ob-Rb, JAK2 and/or STAT3 expression (Myers 
et al. 2008). In addition, in the leptin resistant state, orexigen-
ic neuropeptide Y (NPY) is likely overexpressed due to the 
absence of leptin suppressive effects (Friedman et al. 1998).
As mentioned, obesity is strongly associated with hy-
pothalamic leptin resistance and is accompanied by elevated 
plasma leptin concentrations. However, other alterations in 
the hypothalamic appetite system that favor the orexigenic 
pathways, leptin/insulin resistance and hyperphagia should 
not be overlooked in terms of obesity development and pro-
gression. These changes include abnormal hypothalamus-
adipose axis circadian rhythms, impaired hypothalamic 
sympathetic outflow and/or reduced innervation of the adi-
pose tissue, which may also account for a modified fat cell 
metabolism (Breton 2013).
Adipose tissue was traditionally considered a passive 
organ for triglyceride storage, but this view has been revised. 
We now know that adipose tissue is a metabolically active 
endocrine organ capable of synthesizing a number of biologi-
cally active compounds known as adipocytokines. Adipocyto-
kines are hormones and appetite regulation-related peptides 
implicated in the control of energy balance (Coelho et al. 
2013). Some of these factors act as regulators of adipocyte 
lipid metabolism in an autocrine/paracrine manner, while 
others, like leptin, act as peripheral endocrine signals that 
regulate hypothalamic energy homeostasis (Wang et al. 2008).
Adipose tissue is mostly comprised of adipocytes, cells 
specialized for the storage of triglycerides in the form of lipid 
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droplets under conditions of energy excess. However, when 
the stored energy is required, triglycerides are hydrolyzed 
via lipolytic processes driven by sympathetic innervation. It 
should be kept in mind that both lipogenesis and lipolysis are 
metabolic processes that are highly regulated by a complex 
regulatory network of enzymes and transcription factors. An 
increase in adipose tissue mass can be accomplished either 
by proliferation and differentiation of new adipocytes, which 
is known as hyperplasia, or through triglyceride accumula-
tion in pre-existing or mature adipocytes, which is known 
as hypertrophy (Smith et al. 2006). Of the many transcrip-
tion factors involved in the regulation of these processes, 
PPARγ, is unique in terms of being capable of promoting 
both mechanisms. Namely, PPARγ can increase the expres-
sion of genes that promote FA storage, while repressing genes 
that induce lipolysis and the release of FFAs from adipocytes 
(Berthiaume et al. 2004). The complex regulatory network 
in adipocytes also involves SREBP-1, which belongs to the 
group of related G-protein coupled receptors and is consid-
ered an important factor that assists adipogenesis through 
stimulation of expression of lipogenic genes such as FAS 
(Tontonoz et al. 1993).
Fructose-induced metabolic disturbances: where 
would glucocorticoids fit in?
Glucocorticoids are known for their anti-inflammatory 
and stress response activities; however, they are also consid-
ered as potent modulators of energy metabolism since their 
excess provokes insulin and leptin resistance, affecting the 
control of energy handling in the liver, adipose tissue and 
brain (Di Dalmazi et al. 2012). Although circulating gluco-
corticoids are not elevated in most metabolic diseases, the 
development of metabolic pathologies is usually intensified 
by enhanced glucocorticoid action resulting from increased 
local regeneration of glucocorticoids. In the liver, this in-
creased local regeneration of glucocorticoids has been iden-
tified as a mechanism that favors hepatic fat deposition and 
increases glucose output (Dallman et al. 2007). Thus far, our 
research has shown that changes in glucocorticoid prere-
ceptor metabolism in both liver and visceral adipose tissue 
coincide with metabolic disturbances induced by dietary 
fructose.
Some evident similarities between metabolic syndrome 
and Cushing syndrome, including obesity, hypertension and 
insulin resistance, pointed to glucocorticoids as potential 
contributors to the pathophysiology of the former. The 
main regulator of prereceptor metabolism, which is respon-
sible for the local regeneration of active glucocorticoids, 
is 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), 
a NADPH-dependent enzyme found in the lumen of the 
endoplasmic reticulum, whose reductase activity is driven 
through regeneration of NADPH by hexose 6 phosphate de-
hydrogenase (H6PDH) (Zhang et al. 2009). Many studies 
have revealed that tissue-specific dysregulation of 11βHSD1 
contributes to the pathogenesis of obesity, hypertension 
and insulin resistance. For instance, the levels of 11βHSD1 
mRNA and protein activity were found to be increased in the 
adipose tissue of obese humans and in monogenic obesity in 
rodents (Livingstone et al. 2000; Rask et al. 2001), while oth-
ers reported increased levels of 11βHSD1 mRNA and protein 
activity in the liver of insulin-resistant lean mice (Aoki et al. 
2001). In addition, transgenic overexpression of 11βHSD1 
in rodent adipose tissue causes symptoms of metabolic syn-
drome without changes in circulating glucocorticoids (Masu-
zaki et al. 2001). At the molecular level, the effects of locally 
produced glucocorticoids are mediated by the glucocorticoid 
receptor (GR), a hormone-dependent transcription regulator, 
which upon hormone binding undergoes a conformational 
change that allows for its translocation to the nucleus and 
the regulation of many target genes (Rajapandi et al. 2000).
In the liver, glucocorticoids are involved in the regula-
tion of gluconeogenesis and lipogenesis, which is mediated 
through glucocorticoid-target genes, phosphoenolpyruvate 
carboxykinase (PEPCK) (Cassuto et al. 2005) and lipin-1 
(Bou Khalil et al. 2009). However, the role of GR in the adi-
pose tissue is still controversial. It is well known that glu-
cocorticoids promote preadipocyte conversion to mature 
adipocytes and hyperplasia of adipose tissue, but they are 
also implicated in adipose hypertrophy. On the other hand, 
while their gene regulatory actions facilitate lipolysis in adi-
pocytes, their antilipolytic effects have also been demonstrat-
ed (Campbell et al. 2011). The most interesting aspect of this 
controversy is that these hormones concomitantly affect both 
lipolysis and lipogenesis in adipocytes (Wang et al. 2012). As 
stimulators of lipogenesis, glucocorticoids can increase the 
expression of several key pro-adipogenic and pro-lipogenic 
factors during adipose tissue accumulation, such as PPARγ 
and SREBP-1 (Galitzky et al. 2013). In addition, both PEPCK 
and lipin-1 are subjected to GR regulation in adipose tissue; 
however, in this case PEPCK is involved in the regulation of 
lipid metabolism through glyceroneogenesis (Saltiel et al. 
2001). Conversely, the main glucocorticoid-induced lipolytic 
mechanism is conducted through the direct transcriptional 
control of hormone sensitive lipase (HSL). Namely, the en-
hanced activity of this enzyme contributes to the liberation 
of FFA from the adipose tissue, thus altering their trafficking 
to other organs (Campbell et al. 2011).
We explored the molecular mechanisms that lead to 
metabolic derangements after fructose-containing bever-
age consumption on fructose-fed male Wistar rats. In this 
review, we summarize the findings after the application of 
different amounts of fructose (10% and 60% solutions) over 
a period of nine weeks. The rationale behind the chosen 
fructose concentrations was that 10% fructose solution ap-
proximates sugar beverage consumption in the Western diet, 
whereas 60% fructose aggravates some metabolic syndrome 
indicators, including visceral adiposity and hypertriglyceri-
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demia. Indeed, we concluded that different fructose loads 
were important influences on the metabolic outcome of the 
fructose diet.
The consumption of a 10% fructose solution led to li-
polysis in visceral adipose tissue and to an increased circu-
latory influx of FFA, thus providing the substrates for en-
hanced β oxidation and triglyceride synthesis in the liver. 
These rats also exhibited higher systolic blood pressure and 
elevated triglycerides, but no body-weight gain (Bursac et al. 
2013). On the other hand, rats that drank the 60% fructose 
solution accumulated visceral fat through the activation of 
adipogenesis, which was most likely driven by the hyper-
leptinemia and hypothalamic leptin resistance (Bursac et al. 
2014). Also, the higher dietary fructose burden triggered he-
patic de novo lipogenesis, leading to inhibition of β-oxidation 
and hypertriglyceridemia (Teofilović et al. 2016). Based on 
the data obtained on this animal model, we concluded that 
the intake of a lower concentration of liquid fructose aggra-
vated metabolism, while the higher fructose load led to more 
obvious metabolic disturbances, such as stimulated hepatic 
de novo lipogenesis, visceral adiposity and leptin resistance.
Our main focus is delineated by the proposed triangular 
interplay between three vertices, respectively represented by 
glucocorticoids, glucocorticoid prereceptor metabolism and 
fructose-induced metabolic disturbance. To examine this 
complex transaction, we analyzed the dynamic changes in 
the corticosterone levels in the plasma and tissue, the gluco-
corticoid prereceptor metabolism and GR signaling in the 
liver, hypothalamus and visceral adipose tissue of the rats 
that consumed either a 10% or 60% fructose solution. While 
the 10% fructose-enriched diet did not affect the plasma and 
hepatic corticosterone levels, it significantly elevated corti-
costerone concentration in visceral adipose tissue (Fig. 1). 
The increase in corticosterone concentration in visceral adi-
pose tissue was paralleled by an increase in 11βHSD1, which 
is in accordance with results from other studies on humans 
and animal models demonstrating that fructose consump-
tion upregulates the activity of this enzyme (Morton et al. 
2004). In addition, 11βHSD1 was shown to be regulated in a 
tissue-specific manner and fine-tuned to local glucocorticoid 
concentration independently of its plasma level (London et 
al. 2009). Since the reductase activity of 11βHSD1 is depen-
dent on the regeneration of NADPH cofactor by H6PDH, 
the observed simultaneous elevation of both 11βHSD1 and 
H6PDH is very likely responsible for the increased corticos-
terone concentration in adipose tissue. Finally, as a result 
of increased intracellular ligand concentration, activation 
of the GR was observed. Importantly, these changes in glu-
cocorticoid signaling in the adipose tissue coincided with 
elevated plasma triglyceride and FFA levels, but without the 
enlargement of visceral fat (Bursac et al. 2013). These find-
ings corroborate the results from previous in vitro and in 
vivo studies suggesting that FFA release from adipose tissue 
is the consequence of GR activation and increased lipoly-
sis (Campbell et al. 2011). This assumption was confirmed 
in our study, which revealed an increase in adipocyte HSL 
mRNA level, which is expected, since GR is a known tran-
scriptional regulator of HSL (Fig. 1). In addition, the activat-
ed GR also caused a reduction in PEPCK mRNA in visceral 
adipose tissue, pointing to limited glyceroneogenesis and 
suppressed lipogenesis. Interestingly, the 10% fructose diet 
led to increased 11βHSD1 and H6PDH protein levels in rat 
liver microsomes, which was not reflected as increased tissue 
corticosterone. This finding could be explained by the fact 
that the intrahepatic corticosterone level depends on the bal-
ance between its production by 11βHSD1 and its clearance 
by A-ring reductases. In addition, the observed enhancement 
of hepatic prereceptor metabolism of glucocorticoids can 
stimulate the transcription of proinflammatory cytokines; 
thus the state of inflammation could be the reason for the 
observed retention of GR in the cytoplasm through NF-κB 
interference with its intracellular shuttling (Ignatova et al. 
2009). Hepatic PEPCK expression was also decreased, which 
is consistent with other studies (Axelsen et al. 2010), as well 
as unchanged hepatic GR signaling (Fig. 2). Taking all of 
these observations into account, we propose that 10% fruc-
tose consumption promoted enhanced glucocorticoid signal-
ing in the adipose tissue, which altered the hepatic metabolic 
phenotype by redirecting plasma FFA uptake from adipose 
tissue depots to the liver. As shown in Fig. 2, FFA uptake 
probably stimulated FA oxidation in the liver, which may be 
considered as an adaptive response aimed at protecting the 
liver against lipotoxicity. However, the influx of fructose me-
tabolites was most likely responsible for the observed induc-
tion of lipogenic enzymes, resulting in an increased secretion 
of triglycerides rather than in an ectopic accumulation of 
lipids in the liver and hepatosteatosis (Figs 1 and 2).
Unlike the 10% fructose diet, the 60% fructose-enriched 
diet was associated with a worsening of the metabolic dis-
turbance, primarily manifesting as hypertriglyceridemia and 
increased visceral adiposity (Bursac et al. 2014; Teofilović 
et al. 2016). The amplified effect of the high fructose load 
was reflected in increased nuclear PPARα, and SREBP-1c 
proteins and FAS mRNA, together with unchanged PGC-1α 
and a decreased level of CPT1 in the liver, which led to the 
inhibition of β-oxidation and more pronounced hypertri-
glyceridemia (Fig. 3). These findings suggested that the more 
concentrated fructose solution aggravated the disturbance in 
lipid metabolism in the liver linked with metabolic changes 
in the adipose tissue and the hypothalamus. Namely, the 
long-term ad libitum access to 60% fructose solution led to 
plasma leptin elevation, a reduction in Ob-Rb protein level 
and an elevation in SOCS3 mRNA in the hypothalamus, sug-
gesting that leptin resistance in these animals was a possible 
link between fructose overconsumption and increased adi-
posity. Importantly, the observed hallmarks of leptin resis-
tance were also associated with the upregulated expression of 
orexigenic NPY in the hypothalamus (Fig. 4). Interestingly, 
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Fig. 1. Schematic overview of changes in glucocorticoid signaling and expression of genes involved in lipid metabolism in visceral adipose tissue 
of male rats fed a 10% fructose solution. TG–triglyceride, FFA–free fatty acid, CORT–corticosterone, GR–glucocorticoid receptor, 11βHSD1–11beta-
hydroxysteroid dehydrogenase type 1, H6PDH–hexose 6 phosphate dehydrogenase, PEPCK–phosphoenolpyruvate carboxykinase, HSL–hormone 
sensitive lipase, NADPH–nicotinamide adenine dinucleotide phosphate.
Fig. 2. Schematic overview of hepatic lipid metabolism (β-oxidation and lipogenesis) and glucocorticoid signaling in male rats fed a 10% fructose 
solution. TG–triglyceride, FFA–free fatty acid, CORT–corticosterone, GR–glucocorticoid receptor, 11βHSD1–11beta-hydroxysteroid dehydrogenase 
type 1, H6PDH–hexose 6 phosphate dehydrogenase, PEPCK–phosphoenolpyruvate carboxykinase, HSL–hormone sensitive lipase, NADPH–
nicotinamide adenine dinucleotide phosphate, PPAR–peroxisome proliferator activated receptor, PGC1α–PPARγ-coactivator-1α, CPT1–carnitine 
palmitoyl transferase 1, SREBP–sterol response element binding protein, FAS–fatty acid synthase.
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Fig. 3. Schematic overview of hepatic lipid metabolism (β-oxidation and lipogenesis) and glucocorticoid signaling in male rats fed a 60% fructose 
solution. TG–triglyceride, FFA–free fatty acid, CORT–corticosterone, GR–glucocorticoid receptor, 11βHSD1–11beta-hydroxysteroid dehydrogenase 
type 1, H6PDH–hexose 6 phosphate dehydrogenase, PEPCK–phosphoenolpyruvate carboxykinase, HSL–hormone sensitive lipase, NADPH–
nicotinamide adenine dinucleotide phosphate, PPAR–peroxisome proliferator activated receptor, PGC1α–PPARγ-coactivator-1α, CPT1–carnitine 
palmitoyl transferase 1, SREBP–sterol response element binding protein, FAS–fatty acid synthase.
the 60% fructose diet did not influence the regeneration of 
active glucocorticoids through prereceptor metabolism in the 
hypothalamus, but it significantly increased the level of GR 
protein (Fig. 4). The parallel increase in hypothalamic NPY 
mRNA could link the involvement of glucocorticoids in the 
positive regulation of this orexigenic peptide with the devel-
opment of central leptin resistance. In this way, enhanced 
GR signaling in the brain impacts body weight and adiposity. 
Another important site of glucocorticoid action is visceral 
adipose tissue. After 60% fructose consumption, while the 
plasma corticosterone concentration was unchanged, cor-
ticosterone was significantly decreased in visceral adipose 
tissue despite 11βHSD1 protein elevation (Fig. 5). Such an 
outcome could be due either to the unchanged adipose tis-
sue H6PDH or the enhanced metabolic clearance of active 
glucocorticoids by α- and β-reductases. As shown in Fig. 5, 
the decrease in adipose tissue corticosterone was accompa-
nied by a decline in GR protein in both the cytoplasm and 
nuclei, indicating overall diminishment of glucocorticoid 
signaling, which coincided with unchanged plasma FFA 
levels. However, GR activity is not only ligand-dependent. 
It was previously shown that protein phosphatase 5 is a re-
ciprocal modulator antagonizing the lipolytic actions of GR, 
while simultaneously promoting the adipogenic actions of 
PPARγ (Hinds et al. 2011). Since PPARγ plays a key role in 
linking adipose tissue lipid metabolism to the nutritional 
state, it is tempting to speculate that fructose excess could 
contribute to visceral adiposity through enhanced PPARγ 
activity. As seen in Fig. 5, this hypothesis was confirmed. In 
addition to PPARγ, several other adipo/lipogenic genes and 
transcription factors, including SREBP-1, lipin-1 and FAS, 
were also elevated in the adipose tissue after the 60% fructose 
diet (Bursac et al. 2014). These changes can be considered as 
key molecular events that shift changes in the adipose tissue 
towards adipogenesis, since clearly separated populations of 
small adipocytes were observed in the visceral adipose tissue 
of the 60% fructose-fed rats (Fig. 5). Finally, even though the 
60% dietary fructose diet induced alterations in the expres-
sion of liver glucocorticoid-metabolizing enzymes, the levels 
of GR and its ligand were not affected (Fig. 3). The pattern of 
glucocorticoid-regulated proteins expression was similar to 
that in animals fed with 10% fructose. Hence, we conclude 
that a fructose diet, independently of the applied concen-
tration, does not change the hepatic GR signaling pathway 
downstream of prereceptor metabolism. This conclusion is 
further supported by the finding that the PEPCK mRNA 
level, which is transcriptionally regulated by GR, was not 
changed in the liver of fructose-fed animals. It is indicative, 
however, that fructose-induced metabolic disturbances are 
more likely associated with alterations in GR level and activ-
ity in the hypothalamus and visceral adipose tissue.
22    Biologia Serbica 39(1) 
The role of glucocorticoid hormones in diet-induced metabolic diseases
Fig. 4. Markers of hypothalamic leptin resistance and 
concomitant changes in glucocorticoid signaling in male 
rats fed a 60% fructose solution. TG–triglyceride, CORT–
corticosterone, GR–glucocorticoid receptor, 11βHSD1–
11beta-hydroxysteroid dehydrogenase type 1, H6PDH–
hexose 6 phosphate dehydrogenase, NADPH–nicotinamide 
adenine dinucleotide phosphate, SOCS–suppressor of 
cytokine signaling, NPY–neuropeptide Y, Ob-Rb–long form 
of the leptin receptor.
Concluding remarks
Our findings indicate that long-term fructose intake 
leads to hypothalamic leptin resistance and the develop-
ment of visceral adiposity, but only at a high dietary fructose 
load. The adiposity-related effects of fructose consumption 
involve the interplay between leptin and glucocorticoid sig-
naling at the level of central effector pathways that control 
energy balance. The fructose-induced leptin resistance is a 
critical component of the obesity-promoting vicious cycle 
that results in extreme forms of untreatable obesity (Fig. 6, 
right panel). Although the liver is the central organ of fruc-
tose metabolism, the impact of the glucocorticoid signaling 
pathway on the visceral adipose tissue of fructose-fed rats is 
predominant since glucocorticoids regulate adipocyte storage 
functionality and thus may indirectly influence hepatic lipid 
metabolism (Fig. 6, left panel) and enhance the development 
of metabolic disturbances.
Acknowledgments
All the research presented in this paper was supported 
by the Ministry of Education, Science and Technological De-
velopment of Serbia (Project No. III41009).
References
Aoki K, Homma M, Hirano T, Oka K, Satoh S, Mukasa K, Ito S, Sekihara H. 
2001. MRNA and enzyme activity of hepatic 11beta-hydroxysteroid 
dehydrogenase type 1 are elevated in C57BL/KsJ-db/db mice. Life 
Sciences. 69(21):2543-2549.
Biologia Serbica 39(1)    23
A. Djordjevic et al.
Axelsen LN, Lademann JB, Petersen JS, Holstein-Rathlou NH, Ploug 
T, Prats C, Pedersen HD, Kjolbye AL. 2010. Cardiac and metabolic 
changes in long-term high fructose-fat fed rats with severe obesity 
and extensive intramyocardial lipid accumulation. American 
Journal of Physiology: Regulatory, Integrative and Comparative 
Physiology. 298(6):R1560-1570.
Berthiaume M, Sell H, Lalonde J, Gelinas Y, Tchernof A, Richard D, 
Deshaies Y. 2004. Actions of PPARgamma agonism on adipose 
tissue remodeling, insulin sensitivity, and lipemia in absence of 
glucocorticoids. American Journal of Physiology: Regulatory, 
Integrative and Comparative Physiology. 287(5):R1116-1123.
Bou Khalil M, Sundaram M, Zhang HY, Links PH, Raven JF, Manmontri 
B, Sariahmetoglu M, Tran K, Reue K, Brindley DN, et al. 2009. The 
level and compartmentalization of phosphatidate phosphatase-1 
(lipin-1) control the assembly and secretion of hepatic VLDL. 
Journal of Lipid Research. 50(1):47-58.
Breton C. 2013. The hypothalamus-adipose axis is a key target 
of developmental programming by maternal nutritional 
manipulation. Journal of Endocrinology. 216(2):R19-31.
Bursac BN, Djordjevic AD, Vasiljevic AD, Milutinovic DD, Velickovic NA, 
Nestorovic NM, Matic GM. 2013. Fructose consumption enhances 
glucocorticoid action in rat visceral adipose tissue. Journal of 
Nutritional Biochemistry. 24(6):1166-1172.
Bursac BN, Vasiljevic AD, Nestorovic NM, Velickovic NA, Vojnovic 
Milutinovic DD, Matic GM, Djordjevic AD. 2014. High-fructose diet 
leads to visceral adiposity and hypothalamic leptin resistance in 
Fig. 5. Histological examination of visceral adipose tissue with a schematic representation of the molecular changes in glucocorticoid signaling and 
lipid metabolism gene expression in male rats after a 60% fructose diet. TG–triglyceride, FFA–free fatty acid, CORT–corticosterone, GR–glucocorticoid 
receptor, 11βHSD1–11beta-hydroxysteroid dehydrogenase type 1, H6PDH–hexose 6 phosphate dehydrogenase, PEPCK–phosphoenolpyruvate 
carboxykinase, HSL–hormone sensitive lipase, NADPH–nicotinamide adenine dinucleotide phosphate, PPAR–peroxisome proliferator activated 
receptor, SREBP–sterol response element binding protein, FAS–fatty acid synthase.
Fig. 6. Summarized overview of different impact of 
applied fructose diets on glucocorticoid signaling in the 
hypothalamus, visceral adipose tissue and liver of male 
rats. Note that the adiposity-related effects of fructose 
consumption involve the interplay between leptin and 
glucocorticoid signaling at the level of hypothalamus but 
only at higher fructose loads. Glucocorticoid signaling 
pathway in visceral adipose tissue of rats fed with lower 
fructose concentration may indirectly influence hepatic lipid 
metabolism through free fatty acid release.
24    Biologia Serbica 39(1) 
The role of glucocorticoid hormones in diet-induced metabolic diseases
male rats–do glucocorticoids play a role? Journal of Nutritional 
Biochemistry. 25(4):446-455.
Campbell JE, Peckett AJ, D’Souza AM, Hawke TJ, Riddell MC. 2011. 
Adipogenic and lipolytic effects of chronic glucocorticoid exposure. 
American Journal of Physiology: Cell Physiology. 300(1):C198-209.
Cassuto H, Kochan K, Chakravarty K, Cohen H, Blum B, Olswang Y, Hakimi 
P, Xu C, Massillon D, Hanson RW, et al. 2005. Glucocorticoids regulate 
transcription of the gene for phosphoenolpyruvate carboxykinase 
in the liver via an extended glucocorticoid regulatory unit. Journal 
of Biological Chemistry. 280(40):33873-33884.
Coelho M, Oliveira T, Fernandes R. 2013. Biochemistry of adipose tissue: 
an endocrine organ. Archives of Medical Science. 9(2):191-200.
Dalen KT, Ulven SM, Arntsen BM, Solaas K, Nebb HI. 2006. PPARalpha 
activators and fasting induce the expression of adipose 
differentiation-related protein in liver. Journal of Lipid Research. 
47(5):931-943.
Dallman MF, Akana SF, Pecoraro NC, Warne JP, la Fleur SE, Foster MT. 
2007. Glucocorticoids, the etiology of obesity and the metabolic 
syndrome. Current Alzheimer Research. 4(2):199-204.
Di Dalmazi G, Pagotto U, Pasquali R, Vicennati V. 2012. Glucocorticoids 
and type 2 diabetes: from physiology to pathology. Journal of 
Nutrition and Metabolism. 2012:ID525093.
Djouadi F, Brandt JM, Weinheimer CJ, Leone TC, Gonzalez FJ, Kelly DP. 
1999. The role of the peroxisome proliferator-activated receptor 
alpha (PPAR alpha) in the control of cardiac lipid metabolism. 
Prostaglandins, Leukotrienes, and Essential Fatty Acids. 60(5-
6):339-343.
Friedman JM, Halaas JL. 1998. Leptin and the regulation of body weight 
in mammals. Nature. 395(6704):763-770.
Galitzky J, Bouloumie A. 2013. Human visceral-fat-specific glucocorticoid 
tuning of adipogenesis. Cell Metabolism. 18(1):3-5.
Golay A, Bobbioni E. 1997. The role of dietary fat in obesity. International 
Journal of Obesity and Related Metabolic Disorders. 21 (Suppl 
3):S2-11.
Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. 
1992. Prospective analysis of the insulin-resistance syndrome 
(syndrome X). Diabetes. 41(6):715-722.
Hanover LM, White JS. 1993. Manufacturing, composition, and 
applications of fructose. American Journal of Clinical Nutrition. 
58(5 Suppl):724S-732S.
Havel PJ. 2005. Dietary fructose: implications for dysregulation of 
energy homeostasis and lipid/carbohydrate metabolism. Nutrition 
Reviews. 63(5):133-157.
Hinds TD Jr, Stechschulte LA, Cash HA, Whisler D, Banerjee A, Yong 
W, Khuder SS, Kaw MK, Shou W, Najjar SM, et al. 2011. Protein 
phosphatase 5 mediates lipid metabolism through reciprocal 
control of glucocorticoid receptor and peroxisome proliferator-
activated receptor-gamma (PPARgamma). Journal of Biological 
Chemistry. 286(50):42911-42922.
Horton JD, Goldstein JL, Brown MS. 2002. SREBPs: activators of the 
complete program of cholesterol and fatty acid synthesis in the 
liver. Journal of Clinical Investigation. 109(9):1125-1131.
Huang PL. 2009. A comprehensive definition for metabolic syndrome. 
Disease Models & Mechanisms. 2(5-6):231-237.
Ignatova ID, Kostadinova RM, Goldring CE, Nawrocki AR, Frey FJ, Frey 
BM. 2009. Tumor necrosis factor-alpha upregulates 11beta-
hydroxysteroid dehydrogenase type 1 expression by CCAAT/
enhancer binding protein-beta in HepG2 cells. American Journal of 
Physiology: Endocrinology and Metabolism. 296(2):E367-377.
Jürgens H, Haass W, Castañeda TR, Schürmann A, Koebnick C, 
Dombrowski F, Otto B, Nawrocki AR, Scherer PE, Spranger J, et al. 
2005. Consuming fructose-sweetened beverages increases body 
adiposity in mice. Obesity Research. 13(7):1146-1156.
Kaur J. 2014. A comprehensive review on metabolic syndrome. 
Cardiology Research and Practice. 2014:943162.
Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon 
CJ, Walker BR. 2000. Understanding the role of glucocorticoids in 
obesity: tissue-specific alterations of corticosterone metabolism in 
obese Zucker rats. Endocrinology. 141(2):560-563.
London E, Castonguay TW. 2009. Diet and the role of 11beta-
hydroxysteroid dehydrogenase-1 on obesity. Journal of Nutritional 
Biochemistry. 20(7):485-493.
Malik VS, Popkin BM, Bray GA, Despres JP, Willett WC, Hu FB. 2010. Sugar-
sweetened beverages and risk of metabolic syndrome and type 2 
diabetes: a meta-analysis. Diabetes Care. 33(11):2477-2483.
Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, 
Flier JS. 2001. A transgenic model of visceral obesity and the 
metabolic syndrome. Science. 294(5549):2166-2170.
Miller A, Adeli K. 2008. Dietary fructose and the metabolic syndrome. 
Current Opinion in Gastroenterology. 24(2):204-209.
Morton NM, et al. 2004. Novel adipose tissue-mediated resistance to diet-
induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase 
type 1-deficient mice. Diabetes. 53(4):931-938.
Myers MG, Cowley MA, Munzberg H. 2008. Mechanisms of leptin action 
and leptin resistance. Annual Review of Physiology. 70:537-556.
Oswal A, Yeo G. 2010. Leptin and the control of body weight: a review 
of its diverse central targets, signaling mechanisms, and role in the 
pathogenesis of obesity. Obesity (Silver Spring). 18(2):221-229.
Pitsavos C, Panagiotakos D, Weinem M, Stefanadis C. 2006. Diet, exercise 
and the metabolic syndrome. The Review of Diabetic Studies. 
3(3):118-126.
Rajapandi T, Greene LE, Eisenberg E. 2000. The molecular chaperones 
Hsp90 and Hsc70 are both necessary and sufficient to activate 
hormone binding by glucocorticoid receptor. Journal of Biological 
Chemistry. 275(29):22597-22604.
Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson 
O, Walker BR. 2001. Tissue-specific dysregulation of cortisol 
metabolism in human obesity. Journal of Clinical Endocrinology 
and Metabolism. 86(3):1418-1421.
Reaven GM. 1988. Banting lecture 1988. Role of insulin resistance in 
human disease. Diabetes. 37(12):1595-1607.
Saltiel AR, Kahn CR. 2001. Insulin signalling and the regulation of glucose 
and lipid metabolism. Nature. 414(6865):799-806.
Smith J, Al-Amri M, Dorairaj P, Sniderman A. 2006. The adipocyte life 
cycle hypothesis. Clinical Science (London). 110(1):1-9.
Sun SZ, Empie MW. 2012. Fructose metabolism in humans - what 
isotopic tracer studies tell us. Nutrition & Metabolism. 9(1):89.
Tappy L, Le KA. 2010. Metabolic effects of fructose and the worldwide 
increase in obesity. Physiological Reviews. 90(1):23-46.
Teofilović A, Bursać B, Veličković N, Djordjevic A, Vojnovic Milutinovic 
D, Veličković N. 2016. High dietary fructose load aggravates lipid 
metabolism in the liver of Wistar rats through imbalance between 
lipogenesis and fatty acid oxidation. Turkish Journal of Biology. 
40:1235-1242.
Tontonoz P, Kim JB, Graves RA, Spiegelman BM. 1993. ADD1: a novel 
helix-loop-helix transcription factor associated with adipocyte 
determination and differentiation. Molecular and Cellular Biology. 
13(8):4753-4759.
Walker RW, Dumke KA, Goran MI. 2014. Fructose content in popular 
beverages made with and without high-fructose corn syrup. 
Nutrition. 30(7-8):928-935.
Wang JC, Gray NE, Kuo T, Harris C. 2012. Regulation of triglyceride 
metabolism by glucocorticoid receptor. Cell Bioscience. 2(1):19.
Wang P, Mariman E, Renes J, Keijer J. 2008. The secretory function of 
adipocytes in the physiology of white adipose tissue. Journal of 
Cellular Physiology. 216(1):3-13.
Zhang YL, Zhong X, Gjoka Z, Li Y, Stochaj W, Stahl M, Kriz R, Tobin JF, 
Erbe D, Suri V. 2009. H6PDH interacts directly with 11beta-HSD1: 
implications for determining the directionality of glucocorticoid 
catalysis. Archives of Biochemistry and Biophysics. 483(1):45-54.
Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. 2005. The metabolic 
syndrome: a global public health problem and a new definition. 
Journal of Atherosclerosis and Thrombosis. 12(6):295-300.
Biologia Serbica 39(1)    25
